Comparative Effectiveness of Tocilizumab vs Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease: An Emulated Target Trial

James Cheng Chung Wei, MD, PhD, and Po-Cheng Shih, MD, join CHEST® Journal Podcast Moderator Alice Gallo De Moraes, MD, FCCP, to discuss their research into the comparative effectiveness and safety of tocilizumab and rituximab in patients with rheumatoid arthritis-associated interstitial lung disease. DOI: 10.1016/j.chest.2025.09.009 Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers’ opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine.

You can listen to Comparative Effectiveness of Tocilizumab vs Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease: An Emulated Target Trial online on Radio and Podcast. Open the player on this page to stream the available audio.

Comparative Effectiveness of Tocilizumab vs Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease: An Emulated Target Trial is an episode from CHEST Journal Podcasts by American College of Chest Physicians.

This episode is 22:37 long.

This episode was published on Feb 2, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from CHEST Journal Podcasts when more episodes are available from the podcast feed.